Promise of BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Medical Xpress Article Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts Life Science Investing
Kite's Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma Pharmaceutical Investing
Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Pharmaceutical Investing
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer Pharmaceutical Investing
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy Pharmaceutical Investing
Phase 3 Study Shows XTANDI® plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer Life Science Investing
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer Life Science Investing
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID Life Science Investing
Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call Pharmaceutical Investing
